Edition:
United Kingdom

People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

21.96USD
18 Jun 2019
Change (% chg)

-- (--)
Prev Close
$21.96
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
165,020
52-wk High
$47.20
52-wk Low
$21.31

Dobmeier, Eric 

Mr. Eric L. Dobmeier is an Independent Director of the Company. He has served as President and Chief Executive Officer of Chinook Therapeutics, Inc., a biotechnology company, since April 2019. From January 2018 to June 2018, Mr. Dobmeier was President and Chief Executive Officer of Silverback Therapeutics, Inc, a biotechnology company. Previously, he was at Seattle Genetics, Inc., a biotechnology company, where he held positions of increasing responsibility for more than 15 years, most recently as Chief Operating Officer from June 2011 to December 2017. Prior to joining Seattle Genetics, Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP, where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier received a J.D. from the University of California, Berkeley School of Law and an A.B. in History from Princeton University. We believe that Mr. Dobmeier’s legal, business development and operating experience and years of senior management experience at a public biotechnology company provide him with the qualifications and skills to serve as a director of our company.

Basic Compensation

Total Annual Compensation, USD 63,333
Restricted Stock Award, USD 68,475
Long-Term Incentive Plans, USD --
All Other, USD 128,281
Fiscal Year Total, USD 260,089

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Utpal Koppikar

4,220,280

Joseph Newell

2,492,290

Mina Kim

3,384,430

Derrell Porter

1,510,390

Dietmar Berger

4,972,440

Carol Gallagher

269,256
As Of  31 Dec 2018